The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte DES-IDS and DES-RX Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study 

IRB Protocol #: 1707018360

Overview: The purpose of this study is to test the Svelte Drug Eluting Coronary Stent by comparing it to any commercially  approved Abbott Vascular Xience or Boston Scientific Promus Drug Eluting Coronary Stent. The condition being studied is symptomatic ischemic heart disease, such as angina or a previous myocardial infarct, which is plaque formation in the arteries of your heart that requires treatment. This trial is funded by Svelte Medical Systems. 

Patients must:

  • Be older than 18
  • Be diagnosed with coronary artery disease
  • Be an acceptable candidate for stenting
  • Be informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the institutional review board of the clinical site


Patients cannot participate if:

  • Currently on blood thinners such as warfarin
  • Have an allergy to contrast that cannot be premedicated
  • Have an ongoing heart attack
  • Have ongoing liver or kidney disease



Dr. S. Chiu Wong
Principle Investigator
Phone: (212) 746-4644


Dolores Reynolds, RN, BSN
Research Administrator
Phone: (212) 746-4617

Make an Appointment

(646) 962-5558

Weill Cornell Medicine
Division of Cardiology

1305 York Avenue, 8th Floor
New York, NY 10021